Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate versus methotrexate + leflunomide in psoriatic arthritis
NL-OMON46222Phase 4Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Methotrexate monotherapy with Methotrexate + leflunomide (2 arms). Primary endpoint: Difference in PASDAS at 16 weeks. Started Feb 2019; status: active, not recruiting.
02
Drugs
methotrexateleflunomide
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON46222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46222.